Your browser doesn't support javascript.
loading
S2k guidelines for the treatment of psoriasis in children and adolescents - Short version part 2.
Eisert, Lisa; Augustin, Matthias; Bach, Sabine; Dittmann, Martin; Eiler, Renate; Fölster-Holst, Regina; Gerdes, Sascha; Hamm, Henning; Höger, Peter; Horneff, Gerd; von Kiedrowski, Ralph; Philipp, Sandra; Pleimes, Marc; Schlaeger, Martin; Schuster, Volker; Staubach, Petra; Weberschock, Tobias; Werner, Ricardo Niklas; Nast, Alexander; Sticherling, Michael.
Afiliação
  • Eisert L; Charité - University Medicine Berlin, Corporate Member of Freie Universität Berlin, Humboldt University of Berlin, and Berlin Institute of Health, Department of Dermatology, Venereology und Allergology, Division of Evidence-based Medicine (dEBM), Berlin, Germany.
  • Augustin M; University Medical Center Hamburg-Eppendorf, Institute for Health Services Research in Dermatology and Nursing (IVDP), Hamburg, Germany.
  • Bach S; Patient representatives in the German Psoriasis Association.
  • Dittmann M; Charité - University Medicine Berlin, Corporate Member of Freie Universität Berlin, Humboldt University of Berlin, and Berlin Institute of Health, Department of Dermatology, Venereology und Allergology, Division of Evidence-based Medicine (dEBM), Berlin, Germany.
  • Eiler R; Patient representatives in the German Psoriasis Association.
  • Fölster-Holst R; Department of Dermatology, University Medical Center of Schleswig-Holstein, Campus Kiel, Kiel, Germany.
  • Gerdes S; Department of Dermatology, University Medical Center of Schleswig-Holstein, Campus Kiel, Kiel, Germany.
  • Hamm H; Department of Dermatology, Venereology and Allergology, Würzburg University Medical Center, Würzburg, Germany.
  • Höger P; Department of Pediatrics and Pediatric Dermatology/Allergology, Catholic Children's Hospital Wilhelmstift gGmbH, Hamburg, Germany.
  • Horneff G; Department of Pediatric and Adolescent Medicine, Asklepios Medical Center, Sankt Augustin, Germany.
  • von Kiedrowski R; Office-based Dermatologist, Selters/Westerwald, Germany.
  • Philipp S; Office-based Dermatologist (in collaboration with Markus Friedrich MD), Oranienburg, Germany.
  • Pleimes M; Office-based Dermatologist specialized in Pediatric and Adolescent Skin, Heidelberg, Germany.
  • Schlaeger M; Office-based Dermatologist, Oldenburg, Germany.
  • Schuster V; Department of Pediatric and Adolescent Medicine, Leipzig University Medical Center, Leipzig, Germany.
  • Staubach P; Department of Dermatology, Mainz University Medical Center, Mainz, Germany.
  • Weberschock T; Klinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Frankfurt, Frankfurt/Main.
  • Werner RN; Arbeitsgruppe EbM Frankfurt, Institut für Allgemeinmedizin, Goethe-Universität Frankfurt, Frankfurt/Main.
  • Nast A; Charité - University Medicine Berlin, Corporate Member of Freie Universität Berlin, Humboldt University of Berlin, and Berlin Institute of Health, Department of Dermatology, Venereology und Allergology, Division of Evidence-based Medicine (dEBM), Berlin, Germany.
  • Sticherling M; Charité - University Medicine Berlin, Corporate Member of Freie Universität Berlin, Humboldt University of Berlin, and Berlin Institute of Health, Department of Dermatology, Venereology und Allergology, Division of Evidence-based Medicine (dEBM), Berlin, Germany.
J Dtsch Dermatol Ges ; 17(9): 959-973, 2019 Sep.
Article em En | MEDLINE | ID: mdl-31538732
ABSTRACT
The present guidelines are aimed at residents and board-certified physicians in the fields of dermatology, pediatrics, pediatric dermatology and pediatric rheumatology as well as policymakers and insurance funds. They were developed by dermatologists and pediatric dermatologists in collaboration with pediatric rheumatologists using a formal consensus process (S2k). The guidelines highlight topics such as disease severity, quality of life, treatment goals as well as problems associated with off-label drug therapy in children. Trigger factors and diagnostic aspects are discussed. The primary focus is on the various topical, systemic and UV-based treatment options available and includes recommendations for use and treatment algorithms. Other aspects addressed herein include vaccinations in children and adolescents with psoriasis as well as various disease subtypes such as guttate psoriasis, diaper psoriasis, pustular psoriasis and psoriatic arthritis. Finally, we also provide recommendations for imaging studies and the diagnostic workup to rule out tuberculosis prior to initiating systemic treatment. Note This article constitutes part 2 of the Sk2 guidelines for the treatment of psoriasis in children and adolescents. Part 1 was published in last month's issue. It contained introductory remarks and addressed aspects of diagnosis and topical treatment.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Psoríase / Fármacos Dermatológicos Tipo de estudo: Guideline Limite: Adolescent / Child / Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Psoríase / Fármacos Dermatológicos Tipo de estudo: Guideline Limite: Adolescent / Child / Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article